Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,205
datasets available to search
ShareScore release 0.9.0
Dataset results
1,205 results for “vaccine responses”
Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup
ClinicalTrials.gov study NCT04084769. IPD Sharing: YES. Countries: 2. Publications: 1.
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adult
ClinicalTrials.gov study NCT04537234. IPD Sharing: YES. Countries: 1. Publications: 1.
Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
ClinicalTrials.gov study NCT01488890. IPD Sharing: YES. Countries: 1. Publications: 1.
Immunologic Response to Influenza Vaccination in Children and Adolescents
ClinicalTrials.gov study NCT03614975. IPD Sharing: YES. Countries: 1. Publications: 1.
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults
ClinicalTrials.gov study NCT04498832. IPD Sharing: YES. Countries: 1. Publications: 1.
Characterization of the anti-spike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
Open the record for dataset details and reuse information.
Multi-omics analysis of innate and adaptive responses to BCG vaccination reveals epigenetic cell states that predict trained immunity
<p>This repository contains personal immune profiles of 323 healthy individuals (300BCG) subjected to Bacillus Calmette-Guérin (BCG) with blood samples collected immediately before (day 0), and 14 and 90 days after the vaccination. The personal immune profiles comprise:</p> <ul> <li>immune cell concentrations measured with flow cytometry and a hematology analyzer</li> <li>plasma concentrations of 73 circulating inflammatory markers</li> <li>30 measurements of cytokine and lactate production capacity of peripheral blood mononuclear cells (PBMCs) in response to four microbial stimuli (Candida albicans, Escherichia coli lipopolysaccharide [LPS], Staphylococcus aureus, Mycobacterium tuberculosis).</li> </ul> <p>Visit <a href="http://300BCG.bocklab.org/">http://300BCG.bocklab.org/</a> to learn more.</p>
Raw Data for the article: Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients
<p>SARS‐CoV‐2 vaccine is considered the primary health strategy able to end the current COVID‐19 pandemic. This viral infection impacts more severely solid organ transplant recipients (SOTRs) than general population, but the effect of vaccination in this subgroup of immunosuppressed patients is not known due to their exclusion from vaccination trials. Preliminary reports suggest a lower antibody production after BNT162b2 Pfizer/BioNTech mRNA‐vaccine,<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222937/#ajt16702-bib-0001"> 1 </a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222937/#ajt16702-bib-0002">2 </a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222937/#ajt16702-bib-0003">3 </a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222937/#ajt16702-bib-0004">4 </a>but no data are currently available on the elicited virus‐specific T cell responses.</p>
The metabolic hormone adiponectin affects the correlation between nutritional status and pneumococcal vaccine response in vulnerable indigenous children
<p class="MsoNoSpacing"><strong><span>Background:</span></strong><span> Almost 200 million children worldwide are either undernourished or overweight</span><span>. </span><span>Only a few studies have addressed the effect of variation in nutritional status on vaccine response</span><span>. </span><span>We previously demonstrated an association between stunting and an increased post-vaccination 13-valent pneumococcal conjugate vaccine (PCV13) response. In this prospective study, we assessed to what extent metabolic hormones may be a modifier in the association between nutritional status and PCV13 response.</span></p> <p class="MsoNoSpacing"><strong><span>Methods: </span></strong><span>Venezuelan children aged 6 weeks to 59 months were vaccinated with a primary series of PCV13. Nutritional status and serum levels of leptin, adiponectin and ghrelin were measured upon vaccination and their combined effect on serum post-vaccination antibody concentrations was assessed by generalized estimating equations multivariable regression analysis.</span></p> <p class="MsoNoSpacing"><strong><span>Results:</span></strong><span> A total of 210 children were included, of whom 80 were stunted, 81 had a normal weight and 49 were overweight. Overweight children had lower post-vaccination antibody concentrations than normal weight children </span><span>(regression coefficient -1.15, 95% CI -2.22 – -0.072)</span><span>. Additionally, there was a significant adiponectin-nutritional status interaction. In stunted children, higher adiponectin serum concentrations were associated with lower post-PCV13 antibody concentrations </span><span>(regression coefficient -0.19, 95% CI -0.24 – -0.14) </span><span>while the opposite was seen in overweight children </span><span>(regression coefficient 0.14, 95% CI 0.049 – 0.22)</span><span>. </span></p> <p><strong><span>Conclusion:</span></strong><span> Metabolic hormones, in particular adiponectin, may modify the effect of nutritional status on pneumococcal vaccine response. These findings emphasize the importance of further research to better understand the immunometabolic pathways underlying vaccine response and enable a future of optimal personalized vaccination schedules.</span></p>
Data from: A Nonadjuvanted Whole-Inactivated Pneumococcal Vaccine Induces Multiserotype Opsonophagocytic Responses Mediated by Noncapsule-Specific Antibodies
<p><em>Streptococcus pneumoniae</em> (Spn) remains a major cause of global mortality, with extensive antigenic diversity between capsular serotypes that poses an ongoing challenge for vaccine development. Widespread use of pneumococcal conjugate vaccines (PCVs) targeting Spn capsules has greatly reduced infections by vaccine-included serotypes, but has led to increased infections by non-included serotypes. To date, high cost of PCVs has also limited their usefulness in low-income regions where disease burdens are highest. To overcome these limitations, serotype-independent vaccines are being actively researched. We have developed a whole-cell gamma-irradiated Spn vaccine (termed Gamma-PN) providing serotype-independent protection. We demonstrate that Gamma-PN immunization via the clinically relevant intramuscular route induces protein-specific antibodies able to bind numerous non-vaccine encapsulated serotypes, which mediate opsonophagocytic killing and protection against lethal challenges. Gamma-PN induced comparable or superior OPKA responses to serotypes found in the licensed Prevnar13 (PCV13), and a superior response to non-included serotypes, including emergent 22F and 35B. Additionally, despite a lower observed reactogenicity, administration of Gamma-PN without adjuvant resulted in higher OPKA responses and improved protection compared to adjuvanted Gamma-PN. To our knowledge, this has never been demonstrated for a whole-inactivated Spn vaccine. Eliminating the requirement for adjuvant comes with numerous benefits for clinical applications of this vaccine, and poses interesting questions for the inclusion of adjuvant in similar vaccines in development.</p>
Heritability and genome-wide association study of vaccine-induced immune response in Beagles: A pilot study
<p>Both genetic and non-genetic factors contribute to individual variation in the immune response to vaccination. Understanding how genetic background influences variation in both the magnitude and persistence of vaccine-induced immunity is vital for improving vaccine development and identifying possible causes of vaccine failure. Dogs provide a relevant biomedical model for investigating mammalian vaccine genetics; canine breed structure and long linkage disequilibrium simplify genetic studies in this species compared to humans. The objective of this study was to estimate the heritability of the antibody response to vaccination against viral and bacterial pathogens and to identify genes driving variation of the immune response to vaccination in Beagles. Sixty puppies were immunized following a standard vaccination schedule with an attenuated combination vaccine containing antigens for canine adenovirus type 2, canine distemper virus, canine parainfluenza virus, canine parvovirus, and four strains of <em>Leptospira</em> bacteria. Serum antibody measurements for each viral and bacterial component were measured at multiple time points. Heritability estimations and GWAS were conducted using SNP genotypes at 279,902 markers together with serum antibody titer phenotypes. The heritability estimates were: (1) to <em>Leptospira</em> antigens, ranging from 0.178 to 0.628; and (2) to viral antigens, ranging from 0.199 to 0.588. There was not a significant difference between the overall heritability of vaccine-induced immune response to <em>Leptospira</em> antigens compared to viral antigens. Genetic architecture indicates that SNPs of low to high effect contribute to immune response to vaccination. GWAS identified two genetic markers associated with vaccine-induced immune response phenotypes. Collectively, these findings indicate that genetic regulation of the immune response to vaccination is antigen-specific and influenced by multiple genes of small effect.</p>
Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines
<p>Online Supplementary Dataset of the manuscript "Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines"</p>
Source ELISA data for the manuscript "Restrained expansion of the recall germinal center response as biomarker of protection for influenza vaccination in mice"
<p>This repository contains the source ELISA data for the manuscript "Restrained expansion of the recall germinal center response as biomarker of protection for influenza vaccination in mice" currently under review by PLOS ONE.</p> <p>It supports the following figures:</p> <p>Fig 4A: rHA ELISA data miniHA study.xlsx<br> Fig 4B: Competition ELISA data miniHA study.xlsx<br> S7 Fig: Competition ELISA data POC study.xlsx</p> <p> </p> <p>Files include Raw OD's per plate and reported values analysis. </p> <p> </p>
Streptococcus pyogenes pharyngitis elicits diverse antibody responses to key vaccine antigens influenced by the imprint of past infections.
<p>Here you will find the raw data (RawData.RData) and code (CHIVAS_SEROLOGY_Code.Rmd, an R Markdown file) for generating the analysis and figures for the following publication:</p> <p><strong><em>Streptococcus pyogenes</em> pharyngitis elicits diverse antibody responses to key vaccine antigens influenced by the imprint of past infections.</strong></p> <p>Joshua Osowicki1,2,3 #, Hannah R Frost1 #, Kristy I Azzopardi1, Alana L Whitcombe4, Reuben McGregor4, Lauren H. Carlton4, Ciara Baker1, Loraine Fabri1,5,6, Manisha Pandey7, Michael F Good7, Jonathan R. Carapetis8,9,10, Mark J Walker11,12,13, Pierre R Smeesters1,2,5,6, Paul V Licciardi2,14, Nicole J Moreland4 *, Danika L Hill15 *, Andrew C Steer1,2,3 *</p> <p>Provided in the RData file are the following items: </p> <p><strong>Dataframes: </strong></p> <p>"outcome" : clinical variables associated with human challenge for each participant</p> <p>"data" : ELISA and functional antibody responses for human challenge participants. Each timepoint and isotype for each antigen as seperate column)</p> <p>"data_long": Data equivalent to "data" file but in long format, i.e. One column for each antigen, timepoint and isotype as factors. </p> <p>"data.melt" : Data equivalent to "data" file but in longer format , i.e. timepoint, isotype and antigen as factors, 'value' as ELISA AU. </p> <p>"luminex" : IgG responses to 6 antigens analysed by luminex bead-based assay in human challenge participants.</p> <p>"luminex.children" : IgG responses to 6 antigen analysed by luminex bead-based assay in children</p> <p><strong>Vectors:</strong></p> <p>"pharyngitis" : participant "id" for the 19 individuals that developed pharyngitis. </p> <p>"Antigen.Order" : relates to "Main" antigen classification used in Figure 2</p> <p>'additional" : relates to "Additional </p> <p><strong>Function: </strong></p> <p>"custom_theme" : used as a theme when using ggplot to graph. </p> <p>Adobe Illustrator or Inkscape were used to generate the final image files for publication, with some graph editing to axes labels, font size, adding p-values etc. </p> <p> </p> <p><em><strong>Additional files: </strong></em></p> <p> 3 .csv files have been included for download</p> <p>"ELISA_data_wide_format.csv", a wide format data table of 25 human challenge individuals and 219 variables. Equivalent to the 'data' dataframe in the RData file</p> <p>"CHIVAS_luminex.csv", a long format data table of 25 human challenge participants at 1 week, 1 month, and 3 months. Equivalent to the 'luminex' dataframe in the RData file. </p> <p>"Luminex.children.csv", a datatable of 6 luminex variables for 39 children (healthy and post pharyngitis). Equivalent to the 'luminex.children' dataframe in the RData file. </p> <p> </p>
Dataset and R code: Prior exposure to B. pertussis shapes the mucosal antibody response to acellular pertussis booster vaccination
<p>The R code and dataset for the figures created in the Nature communications manuscript titled "<strong>Prior exposure to <em>B. pertussis </em>shapes the mucosal antibody response to acellular pertussis booster vaccination"</strong>.</p> <p>contains:</p> <p>- excel dataset including the parameters needed for the figures</p> <p>- R code document with the code used to produce the figures and statistical analyses</p>
Raw Data for the article: Analysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 Infection
<p><strong>Background:</strong> Several studies have indicated that anti-SARS-CoV-2 mRNA vaccinations are less effective in inducing robust immune responses among solid organ transplant recipients (SOTRs) compared with the immunocompetent. The third dose of vaccine in SOTRs showed promising results of immunogenicity, even though clinical studies have suggested that immunocompromised subjects are less likely to build a protective immune response against SARS-CoV-2 resulting in lower vaccine efficacy for the prevention of severe COVID-19. <strong>Methods:</strong> Serological IgG and IgA were analyzed through CLIA or ELISA, respectively, while Spike-specific T cells were detected by ELISpot assay after the second and third dose of vaccine in 43 SOTRs. <strong>Results:</strong> The third dose induced an improvement in antibody response against SARS-CoV-2. We also reported a strong correlation between specific humoral and cellular responses after the third dose, even though we did not see significant changes in the magnitude of the SARS-CoV-2-specific T cell response. SOTRs who contracted the SARS-CoV-2 infection after the third dose, despite eliciting a positive IgG response, failed to mount an anti-Spike-S1 IgA response, both after the third dose and after SARS-CoV-2 infection. <strong>Conclusions:</strong> We can conclude that serum IgA detection can be helpful, along with IgG detection, for the evaluation of vaccine efficacy, principally in fragile subjects at high risk of infection.</p>
Data from: Genome-wide epitope mapping reveals significant diversity in antibody responses to Coxiella burnetii vaccination and infection
<p><em>Coxiella burnetii</em> is an important zoonotic bacterial pathogen of global importance, causing the disease Q fever in a wide range of animal hosts. Ruminant livestock, in particular sheep and goats, are considered the main reservoir of infection. Vaccination is a key control measure and two commercial vaccines based on formalin-inactivated<em> C. burnetii </em>bacterins are currently available. However, their deployment is limited due to significant reactogenicity in individuals previously sensitized to <em>C. burnetii </em>antigens. Furthermore, these vaccines interfere with available serodiagnostic tests which are also based on <em>C. burnetii</em> bacterin preparations. Subunit vaccines based on recombinant proteins offer significant advantages, as they can be designed to reduce reactogenicity and can be co-designed with defined antigen serodiagnostic tests to allow discrimination between vaccinated and infected individuals. This study aimed to investigate the diversity of antibody responses to <em>C. burnetii </em>vaccination and/or infection in cattle, goats, humans, and sheep through genome-wide linear epitope mapping to identify candidate vaccine and diagnostic antigens within the predicted bacterial proteome. Using high-density peptide microarrays, we analyzed the seroreactivity in 156 serum samples from vaccinated and infected individuals to peptides derived from 2,092 ORFs in the <em>C. burnetii</em> genome. We found significant diversity in the antibody responses within and between species and across different <em>C. burnetii</em> exposure statuses. However, <em>C. burnetii</em> exposure did result in more uniform seroreactivity across species. Through the implementation of three different vaccine candidate methods, we identified 493 candidate protein antigens for protein subunit vaccine design or serodiagnostic, out of which 65 have been previously described. This is the first study to investigate seroreactivity against the entire <em>C. burnetii </em>genome presented as overlapping linear peptides and provides the basis for selection of antigen targets for next generation Q fever vaccines and diagnostic tests.</p>
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
ClinicalTrials.gov study NCT00262002. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
ClinicalTrials.gov study NCT05124509. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers
ClinicalTrials.gov study NCT01298544. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.